RO7795081 + gemfibrozil

RO7795081 + gemfibrozil is a drug combination evaluated in clinical pharmacology studies to assess drug-drug interactions (DDI). RO7795081 (also known as RG6299) is an investigational small molecule inhibitor of Complement Factor D, a key serine protease in the alternative complement pathway, developed by Roche for the treatment of complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy. Gemfibrozil is a fibric acid derivative used to treat hyperlipidemia and is a potent inhibitor of the CYP2C8 enzyme. The combination is primarily studied to determine the impact of CYP2C8 inhibition on the pharmacokinetics of RO7795081, as RO7795081 is a substrate for this metabolic pathway. Characterizing these interactions is essential for establishing safe dosing regimens in patients who may be co-administered other medications that affect CYP2C8 activity.

Other names

RO7795081 and gemfibrozilRO-7795081 and gemfibrozilRO 7795081 and gemfibrozilRG6299 + gemfibrozil